These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1104 related articles for article (PubMed ID: 3876093)

  • 1. In vivo and in vitro analyses of the immunogenicity of B16 melanoma cells.
    Heath W; Boyle W
    Aust J Exp Biol Med Sci; 1985 Apr; 63 ( Pt 2)():163-75. PubMed ID: 3876093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired H-2 expression in B16 melanoma variants.
    Nanni P; Colombo MP; De Giovanni C; Lollini PL; Nicoletti G; Parmiani G; Prodi G
    J Immunogenet; 1983 Oct; 10(5):361-70. PubMed ID: 6644070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H-2-linked genetic control of murine T-cell-mediated lympholysis to autologous cells modified with low concentrations of trinitrobenzene sulfonate.
    Shearer GM; Schmitt-Verhulst AM; Pettinelli CB; Miller MW; Gilheany PE
    J Exp Med; 1979 Jun; 149(6):1407-23. PubMed ID: 109569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells.
    Ashley MP; Kotlarski I
    Cell Immunol; 1986 Aug; 101(1):156-67. PubMed ID: 3742604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth of transplantable melanoma and leukaemia and prevention of virus-induced leukaemia in long lived radiation chimeras constructed with unmanipulated bone marrow.
    Pierpaoli W
    Clin Exp Immunol; 1985 Jan; 59(1):210-6. PubMed ID: 3882284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of alien minor histocompatibility antigens distinct from tumor-specific transplantation antigen on a murine fibrosarcoma.
    Parmiani G; Colombo M; Ballinari D
    Int J Cancer; 1980 Oct; 26(4):461-5. PubMed ID: 7251224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo H-2K and H-2D antigen expression in two allogeneic mouse tumours of low immunogenicity.
    Ashley MP; Kotlarski I
    Immunol Cell Biol; 1987 Aug; 65 ( Pt 4)():323-8. PubMed ID: 3679289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.
    Hussell T; Georgiou A; Sparer TE; Matthews S; Pala P; Openshaw PJ
    J Immunol; 1998 Dec; 161(11):6215-22. PubMed ID: 9834108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo reexpression of H-2 antigens in B16 melanoma cells.
    Lollini PL; Colombo MP; De Giovanni C; Nicoletti G; Parmiani G; Prodi G; Nanni P
    Exp Clin Immunogenet; 1985; 2(1):14-23. PubMed ID: 3939971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of cytotoxic T cells specific for minor histocompatibility antigens by cross challenge in vitro with H-2 disparate adherent cells.
    Pilarski LM; Carayanniotis G
    J Immunol; 1985 Dec; 135(6):3686-90. PubMed ID: 2415580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD3- bone marrow cells augment the generation of cytotoxic T lymphocytes showing a preference for the X-chromosome linked gene product of stimulator cells.
    Oshiro Y; Tanabe MJ
    Microbiol Immunol; 2001; 45(8):591-604. PubMed ID: 11592633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming.
    Bevan MJ
    J Immunol; 1976 Dec; 117(6):2233-8. PubMed ID: 825578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
    Gold JE; Osband ME
    Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of donor lymphoreticular cells in the rejection of B16 melanoma by allogeneic mice.
    Ashman LK; Goh DH; Kotlarski I
    Aust J Exp Biol Med Sci; 1980 Apr; 58(2):159-66. PubMed ID: 7436875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
    Celik C; Lewis DA; Goldrosen MH
    Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.